Join the Oncology Voice Network. Join for Free
A Trip Around the MSL Insights Cycle
MSL insights insight cycle competitive intelligence training MSLs audience understanding

A Trip Around the MSL Insights Cycle


Share This Article


Summary

In this episode, Patrina Pellett and Richard Swank join Tom Caravela to explore the intricacies of the MSL insight cycle. They delve into the growth and insights course, highlighting common mistakes and the importance of training MSLs on inputting insights. The discussion covers the stages of the insight cycle, with a focus on competitive intelligence and the gathering stage. Patrina and Richard emphasize the significance of understanding your audience and effective mechanisms for sharing insights. The episode wraps up by debunking common myths about insights and includes a call to action for listeners.

In this week’s episode, Patrina Pellett and Richard Swank  (both from MSL Growth) join me to take a trip around the MSL Insights Cycle.

Click for Source
MSL insights, insight cycle, competitive intelligence, training MSLs, audience understanding

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Insight about INSIGHTS, and how they can help your MSL career!
Partner Avatar MSL Talk: Tom Caravela, Joe Liberman

Insight about INSIGHTS, and how they can help your MSL career!

Podcast
How to maximize KOL engagement and MSL insights gathering at your next virtual congress with Patrina Pellet
Partner Avatar MSL Talk: Tom Caravela, Patrina Pellet

How to maximize KOL engagement and MSL insights gathering at your next virtual congress with Patrina Pellet

Article
The Oncology Data Network (ODN): Methodology, Challenges, and Achievements
OVN Avatar Ashley Woolmore , Dirk Arnold , Jean‐Yves Blay , Christian Buske , Alfredo Carrato , Winald Gerritsen , Marc Peeters , Jesus Garcia‐Foncillas , David Kerr

The Oncology Data Network (ODN): Methodology, Challenges, and Achievements

Article
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
OVN Avatar Alyson Haslam, PhD; Vinay Prasad, MD, MPH

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs

Article
Loose Regulatory Standards Portend a New Era of Imprecision Oncology
OVN Avatar Ali Raza Khaki

Loose Regulatory Standards Portend a New Era of Imprecision Oncology

Article
Expert perspectives live from ASCO® 2025
Partner Avatar iNIZIO

Expert perspectives live from ASCO® 2025

Explore OVN